Artificial intelligence is increasingly being used in biomedical research to understand complex aging mechanisms and age-related diseases. AI's ability to analyse large datasets quickly is valuable in drug discovery, genomics, and precision medicine, potentially leading to breakthroughs that delay DNA decay, enhance cell repair, and optimise treatments. AI algorithms can also analyse medical images to identify early disease signs, enabling earlier and more effective treatments. AI-driven precision medicine facilitates tailored interventions based on individual genetic profiles, lifestyles, and environments, reducing the risk of age-related diseases.
However, unequal access to AI and longevity technologies could create a new wealth divide, where those who can afford these advancements live significantly longer than those who cannot. This disparity could exacerbate existing socioeconomic inequalities, leading to differences in life expectancy and quality of life across different demographic groups. Ethical considerations, including data privacy, algorithmic bias, and equitable access, must be addressed to ensure AI-driven healthcare solutions benefit all individuals.
Despite the challenges, AI offers the potential to improve both lifespan and healthspan by predicting frailty risks, recommending preventative measures, and promoting overall well-being. Investment in AI-driven longevity research is growing, with the US and China taking the lead. Combining AI with biochemistry may slow down or even reverse the molecular processes of aging. Predictive healthcare models powered by AI can anticipate health issues, enabling proactive measures to enhance life expectancy and quality of life.
